ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ADMA Biologics Announces Proposed Public Offering of Common Stock

Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million Fourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 Million

ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue Estimate

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - President & CEO Brian Lenz - EVP, CFO & General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, November 9, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) Q3 2022 Earnings Call Transcript

Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q3 Loss, Tops Revenue Estimates

3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase

ADMA Biologics Announces Third Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for November 9, 2022, at 4:30 p.m. ET

ADMA Biologics to Report Third Quarter 2022 Financial Results on November 9, 2022

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth

ADMA BioCenters Receives FDA Approval for its Seventh Plasma Collection Center, Located in Greensboro, NC

Arcos Dorados Hlds

Crescent Point Energy

VAALCO Energy

Itau Unibanco Holding S.A.

Kosmos Energy

NL Industries

Some stocks under $10 are cheap for a reason, but there are other stocks under $10 that are solid long-term investments. There are all sorts of equities from which to choose when building your portfolio.

7 A-Rated Stocks to Buy for Less Than $10

AbbVie

Geron

Prometheus Biosciences

SIGA Technologies

Voyager Therapeutics

Axsome Therapeutics

A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter.

7 Top-Rated Biotech Stocks to Buy for Q4

Endo International

Volcon

Which meme penny stocks are you buying right now? The post How to Invest in Meme Penny Stocks in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Invest in Meme Penny Stocks in 2022

ADMA Biologics recently reported their Q2 earnings with impressive revenue growth and improved margins. The company is on clear a path toward profitability. The market seems to have identified the opportunity that ADMA offers and has supported the share after hitting its low in October of last year.

ADMA Biologics: Strong Growth Is Clearing The Path To Profitability

Investors were pleasantly surprised by the company's latest set of quarterly figures.

Why ADMA Biologics Stock Triumphed on Thursday

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - EVP, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics Second Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, August 10, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc. (ADMA) CEO Adam Grossman on Q2 2022 Results - Earnings Call Transcript

2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase

ADMA Biologics Announces Second Quarter 2022 Financial Results and Provides Business Update

Adma Biologics (ADMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Adma Biologics (ADMA) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ET

ADMA Biologics to Report Second Quarter 2022 Financial Results on August 10, 2022

Express

Gerdau

Which penny stocks are you buying right now? The post Need to Knows for Trading Penny Stocks in July  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Need to Knows for Trading Penny Stocks in July

Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022.

ADMA Biologics Announces Addition to the Russell 2000® Index

ADMA reported a great quarter in all respects. Management gave great guidance for 2024-2025 which shows that ADMA is undervalued with an enterprise value of only $324M.

ADMA Biologics: A Path To Profits Looks Clear

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Elliot Wilbur - Raymond James Kristen Kluska - Cantor Fitzgerald Operator Good afternoon, and welcome to the ADMA Biologics First Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, May 11, 2022. At this time, all participants are in a listen-only mode.

ADMA Biologics, Inc.'s (ADMA) CEO Adam Grossman on Q1 2022 Results - Earnings Call Transcript

First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021

ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET

News for ADMA Biologics Stock (ADMA)